DexTech Medical ABXSAT:DEX +0.49%17 9-Day RSI is 50.40 as of Jul. 11, 2026. GuruFocus rates XSAT:DEX with a GF Score™ of 17/100. The stock has 2 warning signs investors should review. Among 1,421 Biotechnology companies, DexTech Medical AB ranks better than 50.81% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for DexTech Medical AB's 9-Day RSI or its related term are showing as below:
XSAT:DEX's 9-Day RSI is ranked better than 50.81% of 1421
companies
in the Biotechnology industry
Industry Median: 49.68
vs XSAT:DEX: 50.40
DexTech Medical AB (XSAT:DEX) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
DexTech Medical AB 9-Day RSI Related Terms
XSAT:DEX vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, DexTech Medical AB's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexTech Medical AB 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DexTech Medical AB's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where DexTech Medical AB's 9-Day RSI falls into.
DexTech Medical AB (XSAT:DEX) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DexTech Medical AB (XSAT:DEX) has a 9-Day RSI of 50.40 as of Jul. 11, 2026. According to the industry distribution chart, DexTech Medical AB ranks #699 out of 1421 companies in the Biotechnology industry, placing it in the top 49.2%.
Is DexTech Medical AB's 9-Day RSI too high?
DexTech Medical AB's current 9-Day RSI is 50.40. The Biotechnology industry median 9-Day RSI is 49.68. DexTech Medical AB's value of 50.40 is 1.4% above this industry median. Based on the distribution chart, DexTech Medical AB ranks #699 out of 1421 companies in the Biotechnology industry, which is above the industry midpoint. Overall, DexTech Medical AB has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DexTech Medical AB ranks #699 out of 1421 companies for 9-Day RSI. This puts DexTech Medical AB in the upper half of its industry. The industry median 9-Day RSI is 49.68. DexTech Medical AB's value of 50.40 is 1.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 49.68, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DexTech Medical AB's current 9-Day RSI of 50.40 is 1.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 49.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexTech Medical AB's current 9-Day RSI is 50.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (XSAT:DEX) has a current 9-Day RSI of 50.40. The current 9-Day RSI is 50.40 and 1.4% above the Biotechnology industry median of 49.68. DexTech Medical AB's overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For DexTech Medical AB (XSAT:DEX), the current 9-Day RSI is 50.40 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
17GF Score
Get the complete analysis for XSAT:DEX
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:DEX has been successfully added to your 